Moderna mRNA flu shot wins FDA approval but awaits CDC recommendations
Moderna said the FDA approved its mRNA influenza vaccine mFlusiva for seasonal flu prevention in adults 50+ in the US. It received traditional approval for ages 50-64 based on a Phase III trial of 40,000+ and accelerated approval for 65+ pending a postmarketing trial. Moderna shares rose 1.77% to $58. CDC recommendations and an ACIP vote are next.
How this was made
The 30-second read
Why it matters
The approval makes mFlusiva the first authorized US mRNA flu vaccine, but commercialization for national programs hinges on CDC recommendations following the mid-October ACIP meeting. Political oversight under RFK Jr and prior HHS mRNA contract cancellations add uncertainty to uptake and guidance.
Market read
Traders get a concrete regulatory milestone (FDA approval) plus a clear next catalyst date (mid-October ACIP) that can drive expectations for vaccine uptake and revenue timing.
What to watch
Postmarketing trial requirements for the 65+ accelerated approval could introduce future evidence risk, and the article highlights prior FDA comparator concerns that may resurface.
Background
The FDA previously issued a rare refuse to file (RTF) letter in February 2026 over comparator choice, then accepted an amended application after meetings; an advisory committee voted unanimously in June.
Ticker impact
Moderna received FDA approval for its mRNA flu vaccine mFlusiva for adults 50+, with CDC recommendation still pending via mid-October ACIP.
Likely supportive bias into the mid-October ACIP meeting, with potential volatility if CDC/ACIP guidance is delayed or politically constrained.
The article reports a fresh FDA approval event and explicitly flags that national immunization use depends on CDC recommendations, making the next regulatory step a tradable timeline.
Market effects
Strengthens the FDA track record for mRNA vaccines in seasonal indications, potentially improving sentiment for the broader mRNA platform narrative.
Primarily US-focused regulatory and immunization-program implications.
Could influence global regulators and procurement discussions for mRNA flu vaccines, though the article is US-specific.
Counterpoint
The FDA approval may not translate into near-term revenue if CDC/ACIP recommendations are delayed or diluted by political controversy around mRNA.
Key entities
- companyModerna
Nasdaq-listed developer of the mRNA influenza vaccine mFlusiva, now FDA-approved for adults 50+.
- regulatorFDA
Approved mFlusiva after an earlier RTF and advisory committee support.
- regulatorCDC
Will issue recommendations that determine whether mFlusiva is used in national immunization programs.
- advisory_committeeACIP
Will meet in mid-October to shape CDC recommendations; also described as politically controversial under RFK Jr.
- productmFlusiva
Moderna’s mRNA influenza vaccine, approved for seasonal influenza prevention in adults 50+.
